Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration
October 01 2018 - 10:00AM
Press Release
1 October 2018
Immunicum AB (publ) Gives Information on Trading Halt and Ongoing
Negotiations for a Potential Collaboration
Immunicum AB
(publ; IMMU.ST) today announced that Nasdaq Stockholm decided to
halt trading in the Company's share as a result of share price
movements. Immunicum cannot assess whether these movements are
related to information leakage from an ongoing negotiation for a
development collaboration.
The Company therefore wishes to
inform that Immunicum is in negotiations with a leading global
pharmaceutical company regarding a development agreement for
ilixadendel, an off the shelf cancer immune primer. It is currently
not possible to assess whether these negotiations will lead to an
agreement.
Under the collaboration agreement
being negotiated, Immunicum expects to get access to a checkpoint
inhibitor to be combined with ilixadencel in the planned Phase II
study, ILIAD. The agreement will not be associated with any
payments to Immunicum.
Immunicum will inform the market
about the outcomes from the ongoing negotiations as soon as more
specific information becomes available.
The information is
such information that Immunicum is obliged to make public pursuant
to EU Market Abuse Regulation. The information was released for
public disclosure through the contact persons detailed below on 1
October 2018 at 4.00 pm CET.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm www.immunicum.com
20181001_Immunicum_Info on
Trading_ENG_Final
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024